Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum -lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model | Zendy

George G. Zhanel | Zendy; Andrew Denisuik | Zendy; Sahil Vashisht | Zendy; C. Yachison | Zendy; Heather J. Adam | Zendy; D. J. Hoban | Zendy

Open Access

Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum -lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model

Author(s) -

George G. Zhanel,

Andrew Denisuik,

Sahil Vashisht,

C. Yachison,

Heather J. Adam,

D. J. Hoban

Publication year - 2014

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dku149

Subject(s) - ertapenem , microbiology and biotechnology , minimum inhibitory concentration , antibacterial agent , pharmacodynamics , escherichia coli , biology , antibiotics , meropenem , pharmacokinetics , antibiotic resistance , pharmacology , biochemistry , gene

We assessed the pharmacodynamic activity of ertapenem against Escherichia coli with reduced susceptibility (MIC 0.12-0.5 mg/L), intermediate resistance (MIC 1.0 mg/L) or resistance (MIC ≥ 2 mg/L) to ertapenem using an in vitro model.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research